Tanvex Biopharma Stock Current Valuation
| 6541 Stock | TWD 68.10 1.70 2.44% |
Valuation analysis of Tanvex BioPharma helps investors to measure Tanvex BioPharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Tanvex BioPharma's price fluctuation is very steady at this time. Calculation of the real value of Tanvex BioPharma is based on 3 months time horizon. Increasing Tanvex BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tanvex stock is determined by what a typical buyer is willing to pay for full or partial control of Tanvex BioPharma. Since Tanvex BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tanvex Stock. However, Tanvex BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 68.1 | Real 67.97 | Hype 68.1 | Naive 71.72 |
The intrinsic value of Tanvex BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tanvex BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tanvex BioPharma helps investors to forecast how Tanvex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tanvex BioPharma more accurately as focusing exclusively on Tanvex BioPharma's fundamentals will not take into account other important factors: Tanvex BioPharma Company Current Valuation Analysis
Tanvex BioPharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tanvex BioPharma Current Valuation | 14.19 B |
Most of Tanvex BioPharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tanvex BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Tanvex BioPharma has a Current Valuation of 14.19 B. This indicator is about the same for the Healthcare average (which is currently at 14.36 B) sector and 205.49% higher than that of the Biotechnology industry. The current valuation for all Taiwan stocks is 14.64% higher than that of the company.
Tanvex Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tanvex BioPharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tanvex BioPharma could also be used in its relative valuation, which is a method of valuing Tanvex BioPharma by comparing valuation metrics of similar companies.Tanvex BioPharma is rated second in current valuation category among its peers.
Tanvex Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Shares Owned By Insiders | 53.74 % | |||
| Shares Owned By Institutions | 4.30 % | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (1.25 B) | |||
| Net Income | (1.54 B) | |||
| Cash And Equivalents | 1.65 B | |||
| Cash Per Share | 5.29 X | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 7.89 X | |||
| Book Value Per Share | 5.35 X | |||
| Cash Flow From Operations | (1.39 B) | |||
| Earnings Per Share | (4.35) X | |||
| Target Price | 52.4 | |||
| Number Of Employees | 23 | |||
| Beta | 0.67 | |||
| Market Capitalization | 17.11 B | |||
| Total Asset | 4.71 B | |||
| Net Asset | 4.71 B |
About Tanvex BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tanvex BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tanvex BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tanvex BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.